Genmab — August 2019
-
Spørg endelig Bulder.

-
Novartis is now responsible for the development and commercialization of ofatumumab in all potential indications, including cancer and autoimmune diseases. Genmab is entitled to potential regulatory and sales milestones, in addition to double digit royalties.
-
På den baggrund klarer aktien det fint indtil videre.
-
Hvordan kan en pre-market order på 3000 stk i USA, hvilket svarer til 300 danske genmab aktier påvirke kursen så meget? eller er det andre ting der spiller ind ?
-
Hvad mener du Michael?
-
Helge/ troede det var derfor kursen pludseligt faldt fra 1361 til 1333 og troede det var pga. den pre-market order. Men det har nok været andre ting så

-
Den slags har ingen betydning. Genmab skred ned med det øvrige marked.
-
Et hurtigt fald kan forstærkesog udnyttes af kortsigtede tradere samt af shortere som har en interesse i at lukke positioner så lavt som muligt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind